An agonist for sigma-2 receptor
Catalog #: B3053 | abID:

Product Details

Alternate Name Lu-28-179; 1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine]; 1'-(4-(1-(p-Fluorophenyl)indol-3-yl)butyl)spiro(phthalan-1,4'-piperidine)
Appearance White solid
CAS # 147817-50-3
Molecular Formula C₃₀H₃₁FN₂O
Molecular Weight 454.6
Purity ≥98%
Solubility ~25 mg/ml in DMSO
InChi InChI=1S/C30H31FN2O/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30/h1-4,8-15,21H,5-7,16-20,22H2
PubChem CID 9829526
MDL Number MFCD00912182
Handling Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
Storage Conditions -20ºC
Shipping Conditions RT
USAGE For Research Use Only! Not For Use in Humans.


Siramesine is an agonist for sigma-2 (σ2) receptor. It is selective for σ2 over σ1 with IC₅₀ values of 0.12 nM and 17 nM respectively. It shows potent anxiolytic-like effects in rodents. The minimal effective dose (MED) is 0.18 nmol/kg (0.1 microg/kg) and 0.00018 nmol/kg (0.1 ng/kg) in rats and mice respectively. It (20-30 μM) induces cell death in HaCaT, Hsc-4, HeLa, MCF-7, SH-SY5Y and glioblastoma cell lines. Siramesine shows anti-viral activity againt SARS-CoV-2 infection in the Vero E6 cell line in an immunofluorescence-based assay (detecting the viral NP protein).

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.